SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Alexandra Beilina, Mark R Cookson, Genes associated with Parkinson's disease: regulation of autophagy and beyond, Journal of Neurochemistry, 2016, 136, 4
  2. 2
    J.G. Goldman, S. Holden, Encyclopedia of Mental Health, 2016,

    CrossRef

  3. 3
    Martijn L.T.M. Müller, Nicolaas I. Bohnen, Vikas Kotagal, Peter J.H. Scott, Robert A. Koeppe, Kirk A. Frey, Roger L. Albin, Clinical markers for identifying cholinergic deficits in Parkinson's disease, Movement Disorders, 2015, 30, 2
  4. 4
    D. Caudal, A. Alvarsson, A. Björklund, P. Svenningsson, Depressive-like phenotype induced by AAV-mediated overexpression of human α-synuclein in midbrain dopaminergic neurons, Experimental Neurology, 2015, 273, 243

    CrossRef

  5. 5
    Roger Kurlan, Bernard Ravina, Shirley Eberly, Anthony E. Lang, Caroline M. Tanner, Kenneth Marek, Karen Marder, James Beck, Robin Elliott, David Oakes, Ira Shoulson, Early Clinical Predictors of Treatment-Resistant and Functional Outcomes in Parkinson's Disease, Movement Disorders Clinical Practice, 2015, 2, 4
  6. 6
    Y. Niu, X. Guo, Y. Chen, C.-E. Wang, J. Gao, W. Yang, Y. Kang, W. Si, H. Wang, S.-H. Yang, S. Li, W. Ji, X.-J. Li, Early Parkinson's disease symptoms in  -synuclein transgenic monkeys, Human Molecular Genetics, 2015, 24, 8, 2308

    CrossRef

  7. 7
    Paolo Solla, Christian Cadeddu, Antonino Cannas, Martino Deidda, Nicola Mura, Giuseppe Mercuro, Francesco Marrosu, Heart rate variability shows different cardiovascular modulation in Parkinson’s disease patients with tremor dominant subtype compared to those with akinetic rigid dominant subtype, Journal of Neural Transmission, 2015, 122, 10, 1441

    CrossRef

  8. 8
    Aaron Kucinski, Roger L. Albin, Cindy Lustig, Martin Sarter, Modeling falls in Parkinson's disease: Slow gait, freezing episodes and falls in rats with extensive striatal dopamine loss, Behavioural Brain Research, 2015, 282, 155

    CrossRef

  9. 9
    J William Langston, Birgitt Schüle, Linda Rees, R Jeremy Nichols, Carrolee Barlow, Multisystem Lewy body disease and the other parkinsonian disorders, Nature Genetics, 2015, 47, 12, 1378

    CrossRef

  10. 10
    Carol P. Weingarten, Mark H. Sundman, Patrick Hickey, Nan-kuei Chen, Neuroimaging of Parkinson's disease: Expanding views, Neuroscience & Biobehavioral Reviews, 2015, 59, 16

    CrossRef

  11. 11
    Yin Xia Chao, Lai Mun Chew, Xiao Deng, Eng-King Tan, Nonmotor symptoms in sporadic versus familial forms of Parkinson's disease, Neurodegenerative Disease Management, 2015, 5, 2, 147

    CrossRef

  12. 12
    Rakshita A. Charan, Matthew J. LaVoie, Pathologic and therapeutic implications for the cell biology of parkin, Molecular and Cellular Neuroscience, 2015, 66, 62

    CrossRef

  13. 13
    Johanna Wilhelmina Maria Aarts, Femke Vennik, Willianne L. D. M. Nelen, Martijn Eijk, Bastiaan R. Bloem, Marjan J. Faber, Jan A. M. Kremer, Personal health communities: a phenomenological study of a new health-care concept, Health Expectations, 2015, 18, 6
  14. 14
    Marios Politis, Flavia Niccolini, Serotonin in Parkinson's disease, Behavioural Brain Research, 2015, 277, 136

    CrossRef

  15. 15
    Kay Seidel, Josefine Mahlke, Sonny Siswanto, Reijko Krüger, Helmut Heinsen, Georg Auburger, Mohamed Bouzrou, Lea T. Grinberg, Helmut Wicht, Horst-Werner Korf, Wilfred den Dunnen, Udo Rüb, The Brainstem Pathologies of Parkinson's Disease and Dementia with Lewy Bodies, Brain Pathology, 2015, 25, 2
  16. 16
    Maurício Guilherme Valente Maturana, Anderson Sá Pinheiro, Theo Luiz Ferraz de Souza, Cristian Follmer, Unveiling the role of the pesticides paraquat and rotenone on α-synuclein fibrillation in vitro, NeuroToxicology, 2015, 46, 35

    CrossRef

  17. 17
    José Christian Machado Ximenes, Kelly Rose Tavares Neves, Luzia Kalyne A. M. Leal, Marta Regina Santos do Carmo, Gerly Anne de Castro Brito, Maria da Graça Naffah-Mazzacoratti, Ésper Abrão Cavalheiro, Glauce Socorro de Barros Viana, Valproic Acid Neuroprotection in the 6-OHDA Model of Parkinson’s Disease Is Possibly Related to Its Anti-Inflammatory and HDAC Inhibitory Properties, Journal of Neurodegenerative Diseases, 2015, 2015, 1

    CrossRef

  18. 18
    S. Koga, N. Aoki, R. J. Uitti, J. A. van Gerpen, W. P. Cheshire, K. A. Josephs, Z. K. Wszolek, J. W. Langston, D. W. Dickson, When DLB, PD, and PSP masquerade as MSA: An autopsy study of 134 patients, Neurology, 2015, 85, 5, 404

    CrossRef

  19. 19
    Scott C. Vermilyea, Marina E. Emborg, α-Synuclein and nonhuman primate models of Parkinson's disease, Journal of Neuroscience Methods, 2015, 255, 38

    CrossRef

  20. 20
    Jianfeng Xiao, Satya Vemula, Zhenyu Yue, Movement Disorders, 2015,

    CrossRef

  21. 21
    Maria Sundberg, Ole Isacson, Advances in stem-cell–generated transplantation therapy for Parkinson's disease, Expert Opinion on Biological Therapy, 2014, 14, 4, 437

    CrossRef

  22. 22
    Sasuk Kim, Ji-Min Park, Jisook Moon, Hyun Jin Choi, Alpha-synuclein interferes with cAMP/PKA-dependent upregulation of dopamine β-hydroxylase and is associated with abnormal adaptive responses to immobilization stress, Experimental Neurology, 2014, 252, 63

    CrossRef

  23. 23
    Paolo Solla, Antonino Cannas, Cesare Salvatore Mulas, Silvia Perra, Andrea Corona, Pier Paolo Bassareo, Francesco Marrosu, Association between fatigue and other motor and non-motor symptoms in Parkinson’s disease patients, Journal of Neurology, 2014, 261, 2, 382

    CrossRef

  24. 24
    James G. Greene, Causes and Consequences of Degeneration of the Dorsal Motor Nucleus of the Vagus Nerve in Parkinson's Disease, Antioxidants & Redox Signaling, 2014, 21, 4, 649

    CrossRef

  25. 25
    Martin Darvas, Charles W. Henschen, Richard D. Palmiter, Contributions of signaling by dopamine neurons in dorsal striatum to cognitive behaviors corresponding to those observed in Parkinson's disease, Neurobiology of Disease, 2014, 65, 112

    CrossRef

  26. 26
    He-Jin Lee, Eun-Jin Bae, Seung-Jae Lee, Extracellular α-synuclein—a novel and crucial factor in Lewy body diseases, Nature Reviews Neurology, 2014, 10, 2, 92

    CrossRef

  27. 27
    Marjolein A. van der Marck, Bastiaan R. Bloem, How to organize multispecialty care for patients with Parkinson's disease, Parkinsonism & Related Disorders, 2014, 20, S167

    CrossRef

  28. 28
    Josiane W. Bortolotto, Giana P. Cognato, Raissa R. Christoff, Laura N. Roesler, Carlos E. Leite, Luiza W. Kist, Mauricio R. Bogo, Monica R. Vianna, Carla D. Bonan, Long-Term Exposure to Paraquat Alters Behavioral Parameters and Dopamine Levels in Adult Zebrafish (Danio Rerio), Zebrafish, 2014, 11, 2, 142

    CrossRef

  29. 29
    Cristian Follmer, Monoamine oxidase and α-synuclein as targets in Parkinson’s disease therapy, Expert Review of Neurotherapeutics, 2014, 14, 6, 703

    CrossRef

  30. 30
    Ellen Gelpi, Judith Navarro-Otano, Eduardo Tolosa, Carles Gaig, Yaroslau Compta, María Jesús Rey, Maria José Martí, Isabel Hernández, Francesc Valldeoriola, Ramon Reñé, Teresa Ribalta, Multiple organ involvement by alpha-synuclein pathology in Lewy body disorders, Movement Disorders, 2014, 29, 8
  31. 31
    Janaína K. Barbiero, Ronise M. Santiago, Daniele Suzete Persike, Maria José da Silva Fernandes, Fernanda S. Tonin, Claudio da Cunha, Suelen Lucio Boschen, Marcelo M.S. Lima, Maria A.B.F. Vital, Neuroprotective effects of peroxisome proliferator-activated receptor alpha and gamma agonists in model of parkinsonism induced by intranigral 1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine, Behavioural Brain Research, 2014, 274, 390

    CrossRef

  32. 32
    Virginie Licker, Pierre R. Burkhard, Proteomics as a new paradigm to tackle Parkinson’s disease research challenges, Translational Proteomics, 2014, 4-5, 1

    CrossRef

  33. 33
    Tonya N. Taylor, Dawid Potgieter, Sabina Anwar, Steven L. Senior, Stephanie Janezic, Sarah Threlfell, Brent Ryan, Laura Parkkinen, Thierry Deltheil, Milena Cioroch, Achilleas Livieratos, Peter L. Oliver, Katie A. Jennings, Kay E. Davies, Olaf Ansorge, David M. Bannerman, Stephanie J. Cragg, Richard Wade-Martins, Region-specific deficits in dopamine, but not norepinephrine, signaling in a novel A30P α-synuclein BAC transgenic mouse, Neurobiology of Disease, 2014, 62, 193

    CrossRef

  34. You have free access to this content34
    T. Hattori, S. Orimo, M. Hallett, T. Wu, A. Inaba, R. Azuma, H. Mizusawa, Relationship and factor structure in multisystem neurodegeneration in Parkinson's disease, Acta Neurologica Scandinavica, 2014, 130, 6
  35. 35
    Osamu Kano, Masayuki Yoshioka, Hiroshi Nagayama, Shinsuke Hamada, Tetsuya Maeda, Takafumi Hasegawa, Taro Kadowaki, Renpei Sengoku, Hiroo Terashi, Taku Hatano, Nobuatsu Nomoto, Manabu Inoue, Hideki Shimura, Tatsuya Takahashi, Tsuyoshi Uchiyama, Hirohisa Watanabe, Satoshi Kaneko, Tetsuya Takahashi, Yasuhiko Baba, Shin-ichiro Kubo, Rhinorrhea in Parkinson's disease: A consecutive multicenter study in Japan, Journal of the Neurological Sciences, 2014, 343, 1-2, 88

    CrossRef

  36. 36
    F. L'Episcopo, C. Tirolo, S. Caniglia, N. Testa, M. C. Morale, M. F. Serapide, S. Pluchino, B. Marchetti, Targeting Wnt signaling at the neuroimmune interface for dopaminergic neuroprotection/repair in Parkinson's disease, Journal of Molecular Cell Biology, 2014, 6, 1, 13

    CrossRef

  37. 37
    Aron S. Buchman, Robert S. Wilson, Lei Yu, Bryan D. James, Patricia A. Boyle, David A. Bennett, Total daily activity declines more rapidly with increasing age in older adults, Archives of Gerontology and Geriatrics, 2014, 58, 1, 74

    CrossRef

  38. 38
    Philip C. Buttery, Roger A. Barker, Treating Parkinson's disease in the 21st century: Can stem cell transplantation compete?, Journal of Comparative Neurology, 2014, 522, 12
  39. 39
    Hilary Afeseh Ngwa, Arthi Kanthasamy, Huajun Jin, Vellareddy Anantharam, Anumantha G. Kanthasamy, Vanadium exposure induces olfactory dysfunction in an animal model of metal neurotoxicity, NeuroToxicology, 2014, 43, 73

    CrossRef

  40. 40
    Jan Leestma, Forensic Neuropathology, Third Edition, 2014,

    CrossRef

  41. 41
    A.B.. West, M. Gray, D.G. Standaert, Reference Module in Biomedical Sciences, 2014,

    CrossRef

  42. 42
    Owen A. Ross, A Prognostic View on the Application of Individualized Genomics in Parkinson’s Disease, Current Genetic Medicine Reports, 2013, 1, 1, 52

    CrossRef

  43. 43
    Joanne Trinh, Matt Farrer, Advances in the genetics of Parkinson disease, Nature Reviews Neurology, 2013, 9, 8, 445

    CrossRef

  44. 44
    Lars Brichta, Paul Greengard, Marc Flajolet, Advances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems, Trends in Neurosciences, 2013, 36, 9, 543

    CrossRef

  45. 45
    J. P. M. van der Vegt, O. J. Hulme, S. Zittel, K. H. Madsen, M. M. Weiss, C. Buhmann, B. R. Bloem, A. Munchau, H. R. Siebner, Attenuated neural response to gamble outcomes in drug-naive patients with Parkinson's disease, Brain, 2013, 136, 4, 1192

    CrossRef

  46. 46
    Alexander Bury, Ilse S. Pienaar, Behavioral testing regimens in genetic-based animal models of Parkinson's disease: Cogencies and caveats, Neuroscience & Biobehavioral Reviews, 2013, 37, 5, 846

    CrossRef

  47. 47
    Martijn L. T. M. Müller, Nicolaas I. Bohnen, Cholinergic Dysfunction in Parkinson’s Disease, Current Neurology and Neuroscience Reports, 2013, 13, 9

    CrossRef

  48. 48
    Miho Murata, Tomoko Okamoto, Depression in Parkinson's disease, Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics, 2013, 50, 6, 752

    CrossRef

  49. You have free access to this content49
    A. Berardelli, G. K. Wenning, A. Antonini, D. Berg, B. R. Bloem, V. Bonifati, D. Brooks, D. J. Burn, C. Colosimo, A. Fanciulli, J. Ferreira, T. Gasser, F. Grandas, P. Kanovsky, V. Kostic, J. Kulisevsky, W. Oertel, W. Poewe, J.-P. Reese, M. Relja, E. Ruzicka, A. Schrag, K. Seppi, P. Taba, M. Vidailhet, EFNS/MDS-ES recommendations for the diagnosis of Parkinson's disease, European Journal of Neurology, 2013, 20, 1
  50. 50
    Tomohiro Omura, Masayuki Kaneko, Yasunobu Okuma, Kazuo Matsubara, Yasuyuki Nomura, Endoplasmic Reticulum Stress and Parkinson’s Disease: The Role of HRD1 in Averting Apoptosis in Neurodegenerative Disease, Oxidative Medicine and Cellular Longevity, 2013, 2013, 1

    CrossRef

  51. 51
    Takashi Inuzuka, Gait disturbance and bradykinesia in elderly, Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics, 2013, 50, 1, 33

    CrossRef

  52. 52
    Hao Wang, Cheng Sun, Yusi Liang, Heying Zhang, Yonggang Tan, Identification of Regulatory Relationships in Parkinson's Disease, Journal of Molecular Neuroscience, 2013, 51, 1, 9

    CrossRef

  53. You have free access to this content53
    S. Mandillo, E. Golini, D. Marazziti, C. Di Pietro, R. Matteoni, G. P. Tocchini-Valentini, Mice lacking the Parkinson's related GPR37/PAEL receptor show non-motor behavioral phenotypes: age and gender effect, Genes, Brain and Behavior, 2013, 12, 4
  54. 54
    Elena M. Vazey, Gary Aston-Jones, New tricks for old dogmas: Optogenetic and designer receptor insights for Parkinson's disease, Brain Research, 2013, 1511, 153

    CrossRef

  55. 55
    Francesco Raudino, Non-cognitive symptoms and related conditions in the Alzheimer’s disease: a literature review, Neurological Sciences, 2013, 34, 8, 1275

    CrossRef

  56. 56
    Fabrizio Stocchi, C. Warren Olanow, Obstacles to the Development of a Neuroprotective Therapy for Parkinson's Disease, Movement Disorders, 2013, 28, 1
  57. 57
    David T. Dexter, Peter Jenner, Parkinson disease: from pathology to molecular disease mechanisms, Free Radical Biology and Medicine, 2013, 62, 132

    CrossRef

  58. 58
    Karl Kieburtz, Kathryn B. Wunderle, Parkinson's disease: Evidence for environmental risk factors, Movement Disorders, 2013, 28, 1
  59. 59
    Mark W Mahowald, Carlos H Schenck, REM sleep behaviour disorder: a marker of synucleinopathy, The Lancet Neurology, 2013, 12, 5, 417

    CrossRef

  60. 60
    Atsushi Takeda, Severe olfactory dysfunction is a predictor of dementia with Parkinson^|^rsquo;s disease, Rinsho Shinkeigaku, 2013, 53, 2, 91

    CrossRef

  61. 61
    Janelle Drouin-Ouellet, Roger A. Barker, The challenges of administering cell-based therapies to patients with Parkinson’s disease, NeuroReport, 2013, 24, 18, 1000

    CrossRef

  62. 62
    Ping Li, Jin Zhu, Qingya Kong, Baifeng Jiang, Xia Wan, Jinfeng Yue, Min Li, Hualiang Jiang, Jian Li, Zhaobing Gao, The ethylene bis-dithiocarbamate fungicide Mancozeb activates voltage-gated KCNQ2 potassium channel, Toxicology Letters, 2013, 219, 3, 211

    CrossRef

  63. 63
    Hongyu Diao, Xinxing Li, Sheng Hu, The identification of dysfunctional crosstalk of pathways in Parkinson disease, Gene, 2013, 515, 1, 159

    CrossRef

  64. 64
    Koichi Wakabayashi, Kunikazu Tanji, Saori Odagiri, Yasuo Miki, Fumiaki Mori, Hitoshi Takahashi, The Lewy Body in Parkinson’s Disease and Related Neurodegenerative Disorders, Molecular Neurobiology, 2013, 47, 2, 495

    CrossRef

  65. 65
    Bianca Marchetti, Francesca L'Episcopo, Maria Concetta Morale, Cataldo Tirolo, Nuccio Testa, Salvo Caniglia, Maria Francesca Serapide, Stefano Pluchino, Uncovering novel actors in astrocyte–neuron crosstalk in Parkinson's disease: the Wnt/β-catenin signaling cascade as the common final pathway for neuroprotection and self-repair, European Journal of Neuroscience, 2013, 37, 10
  66. 66
    Andrea Ciarmiello, Giampiero Giovacchini, Claudio Guidotti, Martina Meniconi, Patrizia Lazzeri, Elena Carabelli, Luigi Mansi, Giuliano Mariani, Duccio Volterrani, Massimo Del Sette, Weighted registration of 123I-FP-CIT SPECT images improves accuracy of binding potential estimates in pathologically low striatal uptake, Journal of Cellular Physiology, 2013, 228, 10
  67. 67
    Martijn L.T.M. Müller, Kirk A. Frey, Myria Petrou, Vikas Kotagal, Robert A. Koeppe, Roger L. Albin, Nicolaas I. Bohnen, β-amyloid and postural instability and gait difficulty in Parkinson's disease at risk for dementia, Movement Disorders, 2013, 28, 3
  68. 68
    Daniel Kremens, Handbook of Parkinson's Disease, Fifth Edition, 2013,

    CrossRef

  69. 69
    Andrew B. West, Michelle Gray, David G. Standaert, Emery and Rimoin's Principles and Practice of Medical Genetics, 2013,

    CrossRef

  70. 70
    Daniel E. Kremens, Handbook of Parkinson’s Disease, 2013,

    CrossRef

  71. 71
    Michel Goedert, Maria Grazia Spillantini, Kelly Del Tredici, Heiko Braak, 100 years of Lewy pathology, Nature Reviews Neurology, 2012, 9, 1, 13

    CrossRef

  72. 72
    Christopher J.R. Dunning, Juan F. Reyes, Jennifer A. Steiner, Patrik Brundin, Can Parkinson's disease pathology be propagated from one neuron to another?, Progress in Neurobiology, 2012, 97, 2, 205

    CrossRef

  73. 73
    Agata Ziomber, Piotr Thor, Anna Krygowska-Wajs, Tomasz Załęcki, Marek Moskała, Irena Romańska, Jerzy Michaluk, Lucyna Antkiewicz-Michaluk, Chronic impairment of the vagus nerve function leads to inhibition of dopamine but not serotonin neurons in rat brain structures, Pharmacological Reports, 2012, 64, 6, 1359

    CrossRef

  74. 74
    Maja Relja, Clinical rating scales, Parkinsonism & Related Disorders, 2012, 18, S229

    CrossRef

  75. 75
    Rekek Negga, J. Andrew Stuart, Morgan L. Machen, Joel Salva, Amanda J. Lizek, S. Jayne Richardson, Amanda S. Osborne, Oriol Mirallas, Kenneth A. McVey, Vanessa A. Fitsanakis, Exposure to Glyphosate- and/or Mn/Zn-Ethylene-bis-Dithiocarbamate-Containing Pesticides Leads to Degeneration of γ-Aminobutyric Acid and Dopamine Neurons in Caenorhabditis elegans, Neurotoxicity Research, 2012, 21, 3, 281

    CrossRef

  76. 76
    Paolo Solla, Antonino Cannas, Federica Carla Ibba, Federico Loi, Marta Corona, Gianni Orofino, Maria Giovanna Marrosu, Francesco Marrosu, Gender differences in motor and non-motor symptoms among Sardinian patients with Parkinson's disease, Journal of the Neurological Sciences, 2012, 323, 1-2, 33

    CrossRef

  77. 77
    Mariapia Vairetti, Andrea Ferrigno, Vittoria Rizzo, Giulia Ambrosi, Alberto Bianchi, Plinio Richelmi, Fabio Blandini, Marie-Therese Armentero, Impaired hepatic function and central dopaminergic denervation in a rodent model of Parkinson's disease: A self-perpetuating crosstalk?, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2012, 1822, 2, 176

    CrossRef

  78. 78
    Pascal. F. Durrenberger, Edna Grünblatt, Francesca S. Fernando, Camelia Maria Monoranu, Jordan Evans, Peter Riederer, Richard Reynolds, David T. Dexter, Inflammatory Pathways in Parkinson’s Disease; A BNE Microarray Study, Parkinson's Disease, 2012, 2012, 1

    CrossRef

  79. 79
    Emily N. Mangano, Darcy Litteljohn, Remmick So, Eric Nelson, Sarah Peters, Cheri Bethune, Jessica Bobyn, Shawn Hayley, Interferon-γ plays a role in paraquat-induced neurodegeneration involving oxidative and proinflammatory pathways, Neurobiology of Aging, 2012, 33, 7, 1411

    CrossRef

  80. 80
    Kelly Del Tredici, Heiko Braak, Lewy pathology and neurodegeneration in premotor Parkinson's disease, Movement Disorders, 2012, 27, 5
  81. 81
    Blake Byers, Hsiao-lu Lee, Renee Reijo Pera, Modeling Parkinson’s Disease Using Induced Pluripotent Stem Cells, Current Neurology and Neuroscience Reports, 2012, 12, 3, 237

    CrossRef

  82. 82
    Todd B. Sherer, Sohini Chowdhury, Katherine Peabody, Deborah W. Brooks, Overcoming obstacles in Parkinson's disease, Movement Disorders, 2012, 27, 13
  83. 83
    Yoland Smith, Thomas Wichmann, Stewart A Factor, Mahlon R DeLong, Parkinson's Disease Therapeutics: New Developments and Challenges Since the Introduction of Levodopa, Neuropsychopharmacology, 2012, 37, 1, 213

    CrossRef

  84. 84
    Nico J. Diederich, André Parent, Parkinson's disease: Acquired frailty of archaic neural networks?, Journal of the Neurological Sciences, 2012, 314, 1-2, 143

    CrossRef

  85. 85
    Elisa Belluzzi, Elisa Greggio, Giovanni Piccoli, Presynaptic dysfunction in Parkinson's disease: a focus on LRRK2, Biochemical Society Transactions, 2012, 40, 5, 1111

    CrossRef

  86. 86
    Owen A Ross, Single gene variants in risk and protection: a new view on the genetic etiology of Parkinson’s disease, Neurodegenerative Disease Management, 2012, 2, 3, 235

    CrossRef

  87. 87
    Temblor en el anciano, FMC - Formación Médica Continuada en Atención Primaria, 2012, 19, 32

    CrossRef

  88. 88
    C. Warren Olanow, José A. Obeso, The significance of defining preclinical or prodromal Parkinson's disease, Movement Disorders, 2012, 27, 5
  89. 89
    Hodaka Yamakado, Yasuhiro Moriwaki, Nobuyuki Yamasaki, Tsuyoshi Miyakawa, Junko Kurisu, Kengo Uemura, Haruhisa Inoue, Makio Takahashi, Ryosuke Takahashi, α-Synuclein BAC transgenic mice as a model for Parkinson's disease manifested decreased anxiety-like behavior and hyperlocomotion, Neuroscience Research, 2012, 73, 2, 173

    CrossRef

  90. 90
    Danna Jennings, David Russell, Ken Marek, John Seibyl, Parkinson's Disease, Second Edition, 2012,

    CrossRef

  91. 91
    Andrew Siderowf, Stanley Fahn, Parkinson's Disease, Second Edition, 2012,

    CrossRef

  92. 92
    Grace Liang, James Tetrud, Parkinson's Disease, Second Edition, 2012,

    CrossRef

  93. 93
    Li Chen, Jian Liu, Qiao Jun Zhang, Jian Jun Feng, Zhen Hua Gui, Umar Ali, Yong Wang, Ling Ling Fan, Chen Hou, Tao Wang, Alterations of emotion, cognition and firing activity of the basolateral nucleus of the amygdala after partial bilateral lesions of the nigrostriatal pathway in rats, Brain Research Bulletin, 2011, 85, 6, 329

    CrossRef

  94. 94
    J.M. Jiménez-Hoyuela García, Aplicaciones neurológicas de la gammagrafía de inervación miocárdica con 123-I-MIBG, Revista Española de Medicina Nuclear, 2011, 30, 3, 197

    CrossRef

  95. 95
    Toru Baba, Atsushi Takeda, Akio Kikuchi, Yoshiyuki Nishio, Yoshiyuki Hosokai, Kazumi Hirayama, Takafumi Hasegawa, Naoto Sugeno, Kyoko Suzuki, Etsuro Mori, Shoki Takahashi, Hiroshi Fukuda, Yasuto Itoyama, Association of olfactory dysfunction and brain. Metabolism in Parkinson's disease, Movement Disorders, 2011, 26, 4
  96. 96
    T. B. Sherer, Biomarkers for Parkinson's Disease, Science Translational Medicine, 2011, 3, 79, 79ps14

    CrossRef

  97. 97
    Zheng-Quan Yu, Mei-Ying Liu, Qing-Xian Ren, Ye Xiong, Jian-Hui Xu, Cheng-Hua Xiao, Dian-Shuai Gao, Dopamine Content in the Striatum and Expression Changes of Bad and Bcl-2 in Elderly Rats with Abnormal Behavior, Neurochemical Research, 2011, 36, 12, 2333

    CrossRef

  98. 98
    Tomoyuki Miyamoto, Masayuki Miyamoto, Masaoki Iwanami, Koichi Hirata, Idiopathic REM Sleep Behavior Disorder: Implications for the Pathogenesis of Lewy Body Diseases, Parkinson's Disease, 2011, 2011, 1

    CrossRef

  99. 99
    G. J. Masilamoni, J. W. Bogenpohl, D. Alagille, K. Delevich, G. Tamagnan, J. R. Votaw, T. Wichmann, Y. Smith, Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys, Brain, 2011, 134, 7, 2057

    CrossRef

  100. 100
    A. Czerniczyniec, A.G. Karadayian, J. Bustamante, R.A. Cutrera, S. Lores-Arnaiz, Paraquat induces behavioral changes and cortical and striatal mitochondrial dysfunction, Free Radical Biology and Medicine, 2011, 51, 7, 1428

    CrossRef

  101. 101
    Takashi Inuzuka, Parkinson's disease in elderly, Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics, 2011, 48, 6, 616

    CrossRef

  102. 102
    C. Warren Olanow, K. McNaught, Parkinson's disease, proteins, and prions: Milestones, Movement Disorders, 2011, 26, 6
  103. 103
    Joshua M. Shulman, Philip L. De Jager, Mel B. Feany, Parkinson's Disease: Genetics and Pathogenesis, Annual Review of Pathology: Mechanisms of Disease, 2011, 6, 1, 193

    CrossRef

  104. 104
    Paul M. A. Antony, Nico J. Diederich, Rudi Balling, Parkinson’s disease mouse models in translational research, Mammalian Genome, 2011, 22, 7-8, 401

    CrossRef

  105. 105
    Charles H. Adler, Premotor Symptoms and Early Diagnosis of Parkinson's Disease, International Journal of Neuroscience, 2011, 121, S2, 3

    CrossRef

  106. 106
    Nicolaas I. Bohnen, Roger L. Albin, The cholinergic system and Parkinson disease, Behavioural Brain Research, 2011, 221, 2, 564

    CrossRef

  107. 107
    Kenneth Marek, Danna Jennings, Shirley Lasch, Andrew Siderowf, Caroline Tanner, Tanya Simuni, Chris Coffey, Karl Kieburtz, Emily Flagg, Sohini Chowdhury, Werner Poewe, Brit Mollenhauer, Paracelsus-Elena Klinik, Todd Sherer, Mark Frasier, Claire Meunier, Alice Rudolph, Cindy Casaceli, John Seibyl, Susan Mendick, Norbert Schuff, Ying Zhang, Arthur Toga, Karen Crawford, Alison Ansbach, Pasquale De Blasio, Michele Piovella, John Trojanowski, Les Shaw, Andrew Singleton, Keith Hawkins, Jamie Eberling, Deborah Brooks, David Russell, Laura Leary, Stewart Factor, Barbara Sommerfeld, Penelope Hogarth, Emily Pighetti, Karen Williams, David Standaert, Stephanie Guthrie, Robert Hauser, Holly Delgado, Joseph Jankovic, Christine Hunter, Matthew Stern, Baochan Tran, Jim Leverenz, Marne Baca, Sam Frank, Cathi-Ann Thomas, Irene Richard, Cheryl Deeley, Linda Rees, Fabienne Sprenger, Elisabeth Lang, Holly Shill, Sanja Obradov, Hubert Fernandez, Adrienna Winters, Daniela Berg, Katharina Gauss, Douglas Galasko, Deborah Fontaine, Zoltan Mari, Melissa Gerstenhaber, David Brooks, Sophie Malloy, Paolo Barone, Katia Longo, Tom Comery, Bernard Ravina, Igor Grachev, Kim Gallagher, Michelle Collins, Katherine L. Widnell, Suzanne Ostrowizki, Paulo Fontoura, Tony Ho, Johan Luthman, Marcel van der Brug, Alastair D. Reith, Peggy Taylor, The Parkinson Progression Marker Initiative (PPMI), Progress in Neurobiology, 2011, 95, 4, 629

    CrossRef

  108. 108
    Varduhi H. Knaryan, Supriti Samantaray, Charlene Le Gal, Swapan K. Ray, Naren L. Banik, Tracking extranigral degeneration in animal models of Parkinson’s disease: quest for effective therapeutic strategies, Journal of Neurochemistry, 2011, 118, 3
  109. 109
    Sowmya V Yelamanchili, Amrita Chaudhuri, Claudia T Flynn, Howard S Fox, Upregulation of cathepsin D in the caudate nucleus of primates with experimental parkinsonism, Molecular Neurodegeneration, 2011, 6, 1, 52

    CrossRef

  110. 110
    T. Polak, D. Weise, F. Metzger, A. C. Ehlis, J. B. Langer, A. Schramm, A. J. Fallgatter, J. Classen, Vagus nerve somatosensory evoked potentials in Parkinson’s disease, Journal of Neurology, 2011, 258, 12, 2276

    CrossRef

  111. 111
    Tonya N. Taylor, W. Michael Caudle, Gary W. Miller, VMAT2-Deficient Mice Display Nigral and Extranigral Pathology and Motor and Nonmotor Symptoms of Parkinson's Disease, Parkinson's Disease, 2011, 2011, 1

    CrossRef

  112. 112
    Aleksandar Videnovic, Cynthia L. Comella, Sleep Disorders, 2011,

    CrossRef

  113. 113
    Stanley Fahn, Joseph Jankovic, Mark Hallett, Principles and Practice of Movement Disorders, 2011,

    CrossRef

  114. 114
    Stanley Fahn, Joseph Jankovic, Mark Hallett, Principles and Practice of Movement Disorders, 2011,

    CrossRef

  115. 115
    Stanley Fahn, Joseph Jankovic, Mark Hallett, Principles and Practice of Movement Disorders, 2011,

    CrossRef

  116. 116
    Silvia A. Mandel, Micaela Morelli, Ilan Halperin, Amos D. Korczyn, Biomarkers for prediction and targeted prevention of Alzheimer’s and Parkinson’s diseases: evaluation of drug clinical efficacy, EPMA Journal, 2010, 1, 2, 273

    CrossRef

  117. 117
    Kazumichi Yamada, Shin-ya Shiraishi, Tadashi Hamasaki, Jun-ichi Kuratsu, Cardiac 123I-MIBG scintigraphy as an outcome-predicting tool for subthalamic nucleus stimulation in Parkinson's disease, Acta Neurochirurgica, 2010, 152, 12, 2063

    CrossRef

  118. 118
    Mohammad M. Herzallah, Ahmed A. Moustafa, Adel J. Misk, Lara H. Al-Dweib, Samer A. Abdelrazeq, Catherine E. Myers, Mark A. Gluck, Depression Impairs Learning Whereas Anticholinergics Impair Transfer Generalization in Parkinson Patients Tested on Dopaminergic Medications, Cognitive and Behavioral Neurology, 2010, 23, 2, 98

    CrossRef

  119. 119
    Robert E. Burke, Evaluation of the Braak staging scheme for Parkinson's disease: Introduction to a panel presentation, Movement Disorders, 2010, 25, S1
  120. 120
    Dennis W. Dickson, Hirotake Uchikado, Hiroshige Fujishiro, Yoshio Tsuboi, Evidence in favor of Braak staging of Parkinson's disease, Movement Disorders, 2010, 25, S1
  121. 121
    Ruksana Azhu Valappil, Jed E. Black, Meredith J. Broderick, Oscar Carrillo, Eric Frenette, Shannon S. Sullivan, Samuel M. Goldman, Caroline M. Tanner, James W. Langston, Exploring the electrocardiogram as a potential tool to screen for premotor Parkinson's disease, Movement Disorders, 2010, 25, 14
  122. 122
    Ted M. Dawson, Han Seok Ko, Valina L. Dawson, Genetic Animal Models of Parkinson's Disease, Neuron, 2010, 66, 5, 646

    CrossRef

  123. 123
    Koichi Wakabayashi, Fumiaki Mori, Kunikazu Tanji, Satoshi Orimo, Hitoshi Takahashi, Involvement of the peripheral nervous system in synucleinopathies, tauopathies and other neurodegenerative proteinopathies of the brain, Acta Neuropathologica, 2010, 120, 1, 1

    CrossRef

  124. 124
    Jose A Obeso, Maria C Rodriguez-Oroz, Christopher G Goetz, Concepcion Marin, Jeffrey H Kordower, Manuel Rodriguez, Etienne C Hirsch, Matthew Farrer, Anthony H V Schapira, Glenda Halliday, Missing pieces in the Parkinson's disease puzzle, Nature Medicine, 2010, 16, 6, 653

    CrossRef

  125. 125
    Zhen-tao Zhang, Xue-bing Cao, Nian Xiong, Hong-cai Wang, Jin-sha Huang, Sheng-gang Sun, Tao Wang, Morin exerts neuroprotective actions in Parkinson disease models in vitro and in vivo, Acta Pharmacologica Sinica, 2010, 31, 8, 900

    CrossRef

  126. 126
    Thomas G. Beach, Charles H. Adler, Lucia I. Sue, Linda Vedders, LihFen Lue, Charles L. White III, Haru Akiyama, John N. Caviness, Holly A. Shill, Marwan N. Sabbagh, Douglas G. Walker, Multi-organ distribution of phosphorylated α-synuclein histopathology in subjects with Lewy body disorders, Acta Neuropathologica, 2010, 119, 6, 689

    CrossRef

  127. 127
    Anthony C. Vernon, Clive Ballard, Michel Modo, Neuroimaging for Lewy body disease: Is the in vivo molecular imaging of α-synuclein neuropathology required and feasible?, Brain Research Reviews, 2010, 65, 1, 28

    CrossRef

  128. 128
    N. I. Bohnen, M. L. T. M. Muller, V. Kotagal, R. A. Koeppe, M. A. Kilbourn, R. L. Albin, K. A. Frey, Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson's disease, Brain, 2010, 133, 6, 1747

    CrossRef

  129. 129
    Stanley Fahn, Parkinson's disease: 10 years of progress, 1997–2007, Movement Disorders, 2010, 25, S1
  130. 130
    Sonja Mendritzki, Saskia Schmidt, Teresa Sczepan, Xin-Ran Zhu, Daniel Segelcke, Hermann Lübbert, Spinal Cord Pathology in Alpha-Synuclein Transgenic Mice, Parkinson's Disease, 2010, 2010, 1

    CrossRef

  131. 131
    Marios Politis, Kit Wu, Clare Loane, Lorenzo Kiferle, Sophie Molloy, David J. Brooks, Paola Piccini, Staging of serotonergic dysfunction in Parkinson's Disease: An in vivo 11C-DASB PET study, Neurobiology of Disease, 2010, 40, 1, 216

    CrossRef

  132. 132
    Igor Branchi, Ivana D’Andrea, Monica Armida, Daniela Carnevale, Maria Antonietta Ajmone-Cat, Antonella Pèzzola, Rosa Luisa Potenza, Maria Grazia Morgese, Tommaso Cassano, Luisa Minghetti, Patrizia Popoli, Enrico Alleva, Striatal 6-OHDA lesion in mice: Investigating early neurochemical changes underlying Parkinson's disease, Behavioural Brain Research, 2010, 208, 1, 137

    CrossRef

  133. 133
    Shen-Yang Lim, Anthony E. Lang, The nonmotor symptoms of Parkinson's disease—An overview, Movement Disorders, 2010, 25, S1
  134. 134
    M. V. Ugryumov, The regulatory functions of the brain: From genome to organism, Herald of the Russian Academy of Sciences, 2010, 80, 3, 199

    CrossRef

  135. 135
    Giovanni D’Andrea, Gianpietro Nordera, Gilberto Pizzolato, Andrea Bolner, Davide Colavito, Raffaella Flaibani, Alberta Leon, Trace amine metabolism in Parkinson's disease: Low circulating levels of octopamine in early disease stages, Neuroscience Letters, 2010, 469, 3, 348

    CrossRef

  136. 136
    Ira L. Goldknopf, Jennifer K. Bryson, Irina Strelets, Silvia Quintero, Essam A. Sheta, Miguel Mosqueda, Helen R. Park, Stanley H. Appel, Holly Shill, Marwan Sabbagh, Bruce Chase, Eric Kaldjian, Katerina Markopoulou, Abnormal serum concentrations of proteins in Parkinson’s disease, Biochemical and Biophysical Research Communications, 2009, 389, 2, 321

    CrossRef

  137. 137
    Birgitt Schüle, Renee A. Reijo Pera, J. William Langston, Can cellular models revolutionize drug discovery in Parkinson's disease?, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2009, 1792, 11, 1043

    CrossRef

  138. 138
    Kathleen M. Fitzpatrick, James Raschke, Marina E. Emborg, Cell-Based Therapies for Parkinson's Disease: Past, Present, and Future, Antioxidants & Redox Signaling, 2009, 11, 9, 2189

    CrossRef

  139. 139
    Estifanos Ghebremedhin, Kelly Del Tredici, James W. Langston, Heiko Braak, Diminished tyrosine hydroxylase immunoreactivity in the cardiac conduction system and myocardium in Parkinson’s disease: an anatomical study, Acta Neuropathologica, 2009, 118, 6, 777

    CrossRef

  140. 140
    Lukas Andereggen, Morten Meyer, Raphael Guzman, Angélique D. Ducray, Hans Rudolf Widmer, Effects of GDNF pretreatment on function and survival of transplanted fetal ventral mesencephalic cells in the 6-OHDA rat model of Parkinson's disease, Brain Research, 2009, 1276, 39

    CrossRef

  141. 141
    J.P.M. van der Vegt, B.F.L. van Nuenen, B.R. Bloem, C. Klein, H.R. Siebner, Imaging the impact of genes on Parkinson's disease, Neuroscience, 2009, 164, 1, 191

    CrossRef

  142. 142
    Emily N. Mangano, Shawn Hayley, Inflammatory priming of the substantia nigra influences the impact of later paraquat exposure: Neuroimmune sensitization of neurodegeneration, Neurobiology of Aging, 2009, 30, 9, 1361

    CrossRef

  143. 143
    Jeff Bronstein, Paul Carvey, Honglei Chen, Deborah Cory-Slechta, Donato DiMonte, John Duda, Paul English, Samuel Goldman, Stephen Grate, Johnni Hansen, Jane Hoppin, Sarah Jewell, Freya Kamel, Walter Koroshetz, James W. Langston, Giancarlo Logroscino, Lorene Nelson, Bernard Ravina, Walter Rocca, George W. Ross, Ted Schettler, Michael Schwarzschild, Bill Scott, Richard Seegal, Andrew Singleton, Kyle Steenland, Caroline M. Tanner, Stephen Van Den Eeden, Marc Weisskopf, Meeting Report: Consensus Statement—Parkinson’s Disease and the Environment: Collaborative on Health and the Environment and Parkinson’s Action Network (CHE PAN) Conference 26–28 June 2007, Environmental Health Perspectives, 2009, 117, 1, 117

    CrossRef

  144. 144
    David Eidelberg, Metabolic brain networks in neurodegenerative disorders: a functional imaging approach, Trends in Neurosciences, 2009, 32, 10, 548

    CrossRef

  145. 145
    Dennis W. Dickson, Hiroshige Fujishiro, Carolyn Orr, Anthony DelleDonne, Keith A. Josephs, Roberta Frigerio, Melinda Burnett, Joseph E. Parisi, Kevin J. Klos, J. Eric Ahlskog, Neuropathology of non-motor features of Parkinson disease, Parkinsonism & Related Disorders, 2009, 15, S1

    CrossRef

  146. 146
    Tomoyuki Miyamoto, Masayuki Miyamoto, Masaoki Iwanami, Keisuke Suzuki, Yuichi Inoue, Koichi Hirata, Odor identification test as an indicator of idiopathic REM sleep behavior disorder, Movement Disorders, 2009, 24, 2
  147. 147
    Wandana Nanhoe-Mahabier, Karlijn F. de Laat, Jasper E. Visser, Jan Zijlmans, Frank-Erik de Leeuw, Bastiaan R. Bloem, Parkinson disease and comorbid cerebrovascular disease, Nature Reviews Neurology, 2009, 5, 10, 533

    CrossRef

  148. 148
    Christopher H. Hawkes, Kelly Del Tredici, Heiko Braak, Parkinson's Disease, Annals of the New York Academy of Sciences, 2009, 1170, 1
  149. 149
    Yvette AM Grimbergen, J William Langston, Raymund AC Roos, Bastiaan R Bloem, Postural instability in Parkinson’s disease: the adrenergic hypothesis and the locus coeruleus, Expert Review of Neurotherapeutics, 2009, 9, 2, 279

    CrossRef

  150. 150
    Stefan Albrecht, Erich Buerger, Potential neuroprotection mechanisms in PD: focus on dopamine agonist pramipexole, Current Medical Research and Opinion, 2009, 25, 12, 2977

    CrossRef

  151. 151
    Randolph Stephenson, Andrew Siderowf, Matthew B. Stern, Premotor Parkinson's disease: Clinical features and detection strategies, Movement Disorders, 2009, 24, S2
  152. 152
    Mark W. Mahowald, Carlos H. Schenck, The REM sleep behavior disorder odyssey, Sleep Medicine Reviews, 2009, 13, 6, 381

    CrossRef

  153. 153
    Saurabh Sen, Andrew B. West, The Therapeutic Potential of LRRK2 and α-Synuclein in Parkinson's Disease, Antioxidants & Redox Signaling, 2009, 11, 9, 2167

    CrossRef

  154. 154
    Saskia Biskup, Andrew B. West, Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2009, 1792, 7, 625

    CrossRef

  155. 155
    Stephen G. Reich, Palliative Medicine, 2009,

    CrossRef

  156. 156
    Robert E. Burke, William T. Dauer, Jean Paul G. Vonsattel, A critical evaluation of the Braak staging scheme for Parkinson's disease, Annals of Neurology, 2008, 64, 5
  157. 157
    Heiko Braak, Kelly Del Tredici, Assessing fetal nerve cell grafts in Parkinson's disease, Nature Medicine, 2008, 14, 5, 483

    CrossRef

  158. 158
    Heiko Braak, Kelly Del Tredici, Assessing fetal nerve cell grafts in Parkinson's disease, Nature Medicine, 2008,

    CrossRef

  159. 159
    Kenneth Marek, Danna Jennings, Gilles Tamagnan, John Seibyl, Biomarkers for Parkison's disease: Tools to assess Parkinson's disease onset and progression, Annals of Neurology, 2008, 64, S2
  160. 160
    Heiko Braak, Kelly Del Tredici, Cortico-basal ganglia-cortical circuitry in Parkinson's disease reconsidered, Experimental Neurology, 2008, 212, 1, 226

    CrossRef

  161. 161
    Travis B. Lewis, David G. Standaert, Design of clinical trials of gene therapy in Parkinson disease, Experimental Neurology, 2008, 209, 1, 41

    CrossRef

  162. 162
    N. I. Bohnen, S. A. Studenski, G. M. Constantine, R. Y. Moore, Diagnostic performance of clinical motor and non-motor tests of Parkinson disease: a matched case–control study, European Journal of Neurology, 2008, 15, 7
  163. 163
    Anthony H. V. Schapira, C. Warren Olanow, Drug selection and timing of initiation of treatment in early Parkinson's disease, Annals of Neurology, 2008, 64, S2
  164. 164
    Shen-Yang Lim, Andrew H. Evans, Janis M. Miyasaki, Impulse Control and Related Disorders in Parkinson's Disease, Annals of the New York Academy of Sciences, 2008, 1142, 1
  165. 165
    Kapil Sethi, Levodopa unresponsive symptoms in Parkinson disease, Movement Disorders, 2008, 23, S3
  166. 166
    Heather Mortiboys, Kelly Jean Thomas, Werner J. H. Koopman, Stefanie Klaffke, Patrick Abou-Sleiman, Simon Olpin, Nicholas W. Wood, Peter H. G. M. Willems, Jan A. M. Smeitink, Mark R. Cookson, Oliver Bandmann, Mitochondrial function and morphology are impaired in parkin-mutant fibroblasts, Annals of Neurology, 2008, 64, 5
  167. 167
    H. Braak, K. Del Tredici, Neue Sicht des kortiko-striato-thalamo-kortikalen Regelkreises bei M. Parkinson, Der Nervenarzt, 2008, 79, 12, 1440

    CrossRef

  168. 168
    Tanya Simuni, Kapil Sethi, Nonmotor manifestations of Parkinson's disease, Annals of Neurology, 2008, 64, S2
  169. 169
    Igor Branchi, Ivana D'Andrea, Monica Armida, Tommaso Cassano, Antonella Pèzzola, Rosa Luisa Potenza, Maria Grazia Morgese, Patrizia Popoli, Enrico Alleva, Nonmotor symptoms in Parkinson's disease: Investigating early-phase onset of behavioral dysfunction in the 6-hydroxydopamine-lesioned rat model, Journal of Neuroscience Research, 2008, 86, 9
  170. 170
    Gurutz Linazasoro, Olfaction testing in PD: Risky conclusions, Movement Disorders, 2008, 23, 7
  171. 171
    Sheila M. Fleming, Nicole A. Tetreault, Caitlin K. Mulligan, Ché B. Hutson, Eliezer Masliah, Marie-Françoise Chesselet, Olfactory deficits in mice overexpressing human wildtype α-synuclein, European Journal of Neuroscience, 2008, 28, 2
  172. 172
    Andrew Siderowf, Matthew B. Stern, Premotor Parkinson's disease: Clinical features, detection, and prospects for treatment, Annals of Neurology, 2008, 64, S2
  173. 173
    Jeffrey H. Kordower, C. Warren Olanow, Regulatable promoters and gene therapy for Parkinson's disease: Is the only thing to fear, fear itself?, Experimental Neurology, 2008, 209, 1, 34

    CrossRef

  174. 174
    Roger L Albin, Robert A Koeppe, Nicolaas I Bohnen, Kristine Wernette, Michael A Kilbourn, Kirk A Frey, Spared caudal brainstem SERT binding in early Parkinson's disease, Journal of Cerebral Blood Flow & Metabolism, 2008, 28, 3, 441

    CrossRef

  175. 175
    Marie-Francoise Chesselet, Sheila Fleming, Farzad Mortazavi, Bernd Meurers, Strengths and limitations of genetic mouse models of Parkinson's disease, Parkinsonism & Related Disorders, 2008, 14, S84

    CrossRef

  176. 176
    Amie L. Peterson, John G. Nutt, Treatment of Parkinson’s disease with trophic factors, Neurotherapeutics, 2008, 5, 2, 270

    CrossRef

  177. 177
    Ming-Kai Chen, Hiroto Kuwabara, Yun Zhou, Robert J. Adams, James R. Brašić, Jennifer L. McGlothan, Tatyana Verina, Neal C. Burton, Mohab Alexander, Anil Kumar, Dean F. Wong, Tomás R. Guilarte, VMAT2 and dopamine neuron loss in a primate model of Parkinson’s disease, Journal of Neurochemistry, 2008, 105, 1
  178. 178
    C. Warren Olanow, Karl Kieburtz, Anthony H. V. Schapira, Why have we failed to achieve neuroprotection in Parkinson's disease?, Annals of Neurology, 2008, 64, S2
  179. 179
    Marie-Francoise Chesselet, Pierre-Olivier Fernagut, Parkinson's Disease, 2008,

    CrossRef

  180. 180
    Leonard Petrucelli, Dennis W. Dickson, Parkinson's Disease, 2008,

    CrossRef

  181. 181
    Vincent Ries, Robert E. Burke, Parkinson's Disease, 2008,

    CrossRef

  182. 182
    Matthew Farrer, Dementias, 2008,

    CrossRef

  183. 183
    Thomas Eckert, Chengke Tang, David Eidelberg, Assessment of the progression of Parkinson's disease: a metabolic network approach, The Lancet Neurology, 2007, 6, 10, 926

    CrossRef

  184. 184
    G. Linazasoro, Classical Parkinson disease versus Parkinson complex – Reflections against staging and in favour of heterogeneity, European Journal of Neurology, 2007, 14, 7
  185. 185
    Werner Poewe, Dysautonomia and cognitive dysfunction in Parkinson's disease, Movement Disorders, 2007, 22, S17
  186. 186
    Nicolaas I. Bohnen, Hiroto Kuwabara, Gregory M. Constantine, Chester A. Mathis, Robert Y. Moore, Grooved pegboard test as a biomarker of nigrostriatal denervation in Parkinson's disease, Neuroscience Letters, 2007, 424, 3, 185

    CrossRef

  187. 187
    Amy B. Manning-BoĞ, J. William Langston, Model fusion: The next phase in developing animal models for parkinson’s disease, Neurotoxicity Research, 2007, 11, 3-4, 219

    CrossRef

  188. 188
    C. H. Hawkes, K. Del Tredici, H. Braak, Parkinson's disease: a dual-hit hypothesis, Neuropathology and Applied Neurobiology, 2007, 33, 6
  189. 189
    Heiko Braak, Magdalena Sastre, Jürgen R. E. Bohl, Rob A. I. de Vos, Kelly Del Tredici, Parkinson’s disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons, Acta Neuropathologica, 2007, 113, 4, 421

    CrossRef

  190. 190
    Alex Iranzo, Carlos H. Schenck, Jorge Fonte, REM sleep behavior disorder and other sleep disturbances in Disney animated films, Sleep Medicine, 2007, 8, 5, 531

    CrossRef

  191. 191
    Alex Iranzo, Cynthia L. Comella, Joan Santamaria, Wolfgang Oertel, Restless legs syndrome in Parkinson's disease and other neurodegenerative diseases of the central nervous system, Movement Disorders, 2007, 22, S18
  192. 192
    S. Wenzel, B. Mollenhauer, C. Trenkwalder, Diagnostik und Therapie von Parkinson-Demenz in der klinischen Praxis, Der Nervenarzt, 2006, 77, 12, 1439

    CrossRef

  193. 193
    James E. Galvin, Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson’s disease: a case for the selective vulnerability of the substantia nigra, Acta Neuropathologica, 2006, 112, 2, 115

    CrossRef

  194. 194
    Arvid Rongve, Dag Aarsland, Management of Parkinson???s Disease Dementia, Drugs & Aging, 2006, 23, 10, 807

    CrossRef

  195. 195
    Alex Iranzo, José Luis Molinuevo, Joan Santamaría, Mónica Serradell, María José Martí, Francesc Valldeoriola, Eduard Tolosa, Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study, The Lancet Neurology, 2006, 5, 7, 572

    CrossRef

  196. 196
    Katherine E. Soderstrom, Shilpa Ramaswamy, C. Warren Olanow, Jeffrey H. Kordower, Animal Models of Parkinson's Disease: The Non-Motor and Non-Dopaminergic Features,
  197. 197
    Karl Kieburtz, Clinical Trial Measures of the Non-Motor Features of Parkinson's Disease,
  198. 198
    Donald E. Frail, Louis Degennaro, Aaron Schimmer, James Kasper, Richard Winneker, Todd B. Sherer, Alison Urkowitz, Kuldip D. Dave, Jill Panetta, John McCall, Drug Repositioning Efforts by Nonprofit Foundations,
  199. 199
    Heiko Braak, Kelly Del Tredici, Non-Dopaminergic Pathology of Parkinson's Disease,
  200. 200
    Samuel M. Goldman, Parkinson's Disease,
  201. 201
    C. Warren Olanow, Anthony E. Lang, Prospects for Neuroprotective Therapies that can Modulate Non-Dopaminergic Features in Parkinson's Disease,
  202. 202
    Mark W. Mahowald, Carlos H. Schenck, Michel A. Cramer Bornemann, REM Sleep Behavior Disorder and Neurodegenerative Disorders,
  203. 203
    Alex Iranzo, Cynthia L. Comella, Restless Legs Syndrome and Akathisia in Parkinson's Disease,
  204. 204
    C. Warren Olanow, Fabrizio Stocchi, Anthony E. Lang, The Dopaminergic and Non-Dopaminergic Features of Parkinson's Disease,
  205. 205
    J. William Langston, The Emerging Entity of Pre-Motor Parkinson's Disease,